In its annual report on the EU budget published today, the European Court of Auditors (ECA) warns that the budget system is too focused on just getting funds spent and needs to place more emphasis on achieving results. As independent auditor, the ECA signed off the 2013 accounts of the European Union, but stresses that the management of EU spending is not yet good enough overall - either at EU level or in the Member States.
Throughout the 2007 to 2013 spending period, say the EU Auditors, the priority was given to spending the money - ‘use it or lose it’ - rather than to achieving good results. For instance, the choice of projects to receive EU funds focused first on disbursing the EU money available, secondly on complying with the rules, and only then - and to a limited extent - on results and impact.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762585-EU-must-focus-on-better-results/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
Ahead of World Mental Health Day, today sees the publication of the Mental Health Integration Index, a new research initiative commissioned by the Janssen Pharmaceutical Companies of Johnson & Johnson and undertaken by the Economist Intelligence Unit.1 The research explores the challenges of integrating Europeans with mental illness into society and employment, within the European Union’s 28 Member States, plus Norway and Switzerland. Countries have been ranked according to their degree of commitment to support those living with mental illness; the findings demonstrate that while there are many examples of good practice across Europe, the whole region has a long way to go before people with mental illness are adequately supported and truly integrated into their communities.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/72762557-janssen-europe-mental-health-index/
Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
EUROPEAN MICROWAVE WEEK - Peregrine Semiconductor Corp. (NASDAQ: PSMI), founder of RF SOI (silicon on insulator) and pioneer of advanced RF solutions, announces the expansion of its integrated product portfolio into DC and X-band frequencies. Today, Peregrine introduces two new integrated products–a True DC switch and an X-band core chip. Built on Peregrine's UltraCMOS® technology, both products integrate RF, digital and analog components onto a single chip. While integration has traditionally offered high-volume markets the benefit of lower cost, Peregrine uses intelligent integration to offer performance advantages in high-performance markets. Peregrine's integrated products offer benefits such as configurability, flexibility, reliability, repeatability, ease-of-use, a reduced form factor and enhanced performance.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7311051-peregrine-semiconductor-expands-integrated-product-portfolio/
France remains the top destination for their North American travelers according to Rail Europe, Inc., the largest distributor of European rail products in North America. According to sales data, Italy and the United Kingdom followed France respectively as the top destinations for Rail Europe travelers this summer.
In reviewing their 2014 sales figures, Rail Europe identified noteworthy travel data that showcases the latest trends and preferences among their North American clients.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7157831-rail-europe-inc-newsroom/
The European Head and Neck Society (EHNS) today announces European-wide ‘Early Diagnosis Days’ taking place on Wednesday 24 September as part of this year’s Head and Neck Cancer Awareness Week (22–26 September). This follows the success of the 2013 campaign, where nearly 100 ‘Early Diagnosis Days’ took place. More than 5,000 patients were seen by a healthcare provider in 1 day, resulting in a referral rate of approximately 5% and multiple diagnoses of the disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762527-EHNS-early-diagnosis-days/
Ulmart’s stunning growth continues unabated as sales for the first six months of 2014 were up 31% in a year-on-year comparison. Sequential quarterly growth increased by 47%.
Ulmart’s half year results put the company at just below GMV of $610 million (VAT included). The company is forecasting GMV of $1.6 billion for the whole year which would put year-end sales at 33% higher than 2013.
Ulmart’s hybrid model which allows customer access to company’s fulfillments centers (currently there are 29 in the European part of Russia) continues to be a disruptive element in e-retail. Due to the particularities of the Russian infrastructure, reliance on last-mile delivery, the obsession of so many other world e-commerce leaders, is simply not a profit-creating option in Russia.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7276256-ulmart-sales-grow-ecommerce/
Frankfurt.
Studierende des Studiengangs Kommunikationsdesign der European School
of Design http://www.europeanschoolofdesign.eu haben eine ungewöhnliche
Illustrationstechnik entwickelt: mit ihren Fingerabdrücken „malen" sie
Motive für eine multimediale Kampagne, die sie in Print, Film, Social
Media, Augmented Reality und PR einsetzen.
Rail Europe Inc., the largest distributor of European rail products in North America, in partnership with Switzerland Tourism and The Swiss Travel System, is offering $75 off each booking that consists of a Swiss Pass or Swiss Flexi Pass and either a Fly Rail Baggage or Fast Baggage service.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7157831-rail-europe-inc-newsroom/
The full set of data from EUCLID, the largest ever prevalence study of Clostridium difficile infection (CDI) across Europe, were presented today at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Data from 482 European hospitals reveal that in a single day, an average of 109 cases of CDI are missed due to a lack of clinical suspicion or inadequate laboratory testing, potentially leading to more than 39,000 missed cases in Europe each year.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400524-EUCLID-clostridium-difficile-infection
